Janet E Pope
Overview
Explore the profile of Janet E Pope including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
8895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrold L, Bingham C, Pope J, OBrien J, Moore P, Roberts-Toler C, et al.
Clin Rheumatol
. 2024 Dec;
44(2):635-648.
PMID: 39707042
Objectives: To compare effectiveness of tofacitinib versus tumor necrosis factor inhibitors (TNFi), and across tofacitinib lines of therapy, in patients with rheumatoid arthritis (RA), using US CorEvitas RA Registry data....
2.
Taylor P, Feist E, Pope J, Nash P, Sibilia J, Caporali R, et al.
Ther Adv Musculoskelet Dis
. 2024 Oct;
16:1759720X241283340.
PMID: 39444594
Rheumatoid arthritis (RA) is an autoimmune disease characterised by persistent inflammation of the synovial joints as well as other tissues and organs. Left untreated, it can lead to joint damage,...
3.
Sun M, Pope J
Curr Opin Rheumatol
. 2024 Oct;
37(1):32-38.
PMID: 39400109
Purpose Of Review: There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Recent Findings: Themes in PMR and GCA include classification...
4.
Fernandez-Codina A, Nevskaya T, Baron M, Appleton C, Cecchini M, Philip A, et al.
Rheumatology (Oxford)
. 2024 Aug;
64(2):888-889.
PMID: 39189988
No abstract available.
5.
Jairath V, Afif W, Bressler B, Pope J, Selchen D, Targownik L, et al.
J Can Assoc Gastroenterol
. 2024 Aug;
7(4):282-289.
PMID: 39139217
Ulcerative colitis (UC) is a severe and debilitating illness that affects the quality of life and physical health of many Canadians. Given the dynamic and progressive nature of the disease,...
6.
Nikolic R, Pardo J, Pope J, Barber C, Barnabe C, Schieir O, et al.
J Rheumatol
. 2024 Jul;
51(9):940-941.
PMID: 39009382
No abstract available.
7.
Hadwen B, Stranges S, Pope J, Bartlett S, Boire G, Bessette L, et al.
Rheumatol Adv Pract
. 2024 Jun;
8(2):rkae066.
PMID: 38895593
Objective: Hypertension (HTN) is a common comorbidity in RA. This study aimed to explore the prevalence and incidence of HTN and baseline factors associated with incident HTN in early RA...
8.
Fernandez-Codina A, Nevskaya T, Baron M, Appleton C, Cecchini M, Philip A, et al.
Rheumatology (Oxford)
. 2024 Apr;
64(3):1476-1481.
PMID: 38652570
Objective: We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). Methods: This phase II...
9.
Bhavsar S, Movahedi M, Cesta A, Pope J, Bombardier C
Joint Bone Spine
. 2024 Apr;
91(4):105732.
PMID: 38583692
Objective: There are various combination conventional synthetic disease-modifying-antirheumatic drug (csDMARD) treatment strategies used in rheumatoid arthritis (RA). A commonly used csDMARD combination is triple therapy with methotrexate (MTX), sulfasalazine (SSZ)...
10.
Khanna D, Kramer F, Hofler J, Ghadessi M, Sandner P, Allanore Y, et al.
Rheumatology (Oxford)
. 2024 Mar;
63(11):3124-3134.
PMID: 38460548
Objective: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. Methods:...